早老性癡呆藥物研究進展

1、How to accelerate AD research 2022-5-82ContentsCurrent situation of AD1What are big companies doing 2Trends3Perspective42022-5-831 Current situation of ADvPopulation：37 million vCauses：too sophisticatedvMarket drugs：Tarcrine，Donepezil，Rivastigmine，Galanthamine，Huperzine，MemantinevSome social activit

2、ies may correlate with AD，but cannot delay the progress of AD2022-5-84Nature Reviews.2010.7:387-3982022-5-852 What are big companies doingvA big cake attracts a lot of big companies，attention，such as Pfizer，Elan，Merk，Novartis and so on2022-5-86BMC Medicine 2009, 7:7 2022-5-87TramiprosatevALZHEMED（Ne

3、urochem Inc.） vThe Phase III trial did not show a beneficial effect on cognition or function，so the development program has been discontinued 2022-5-88Vaccines and antibodiesvAN-1792（Elan）the first-generation amyloid vaccine，Phase II trial was discontinued owing to the development of aseptic meningo

4、encephalitis in 6% of the patientsvACC-001（Elan）prevent the induction of a toxic cellular immune response，in a Phase II clinical trialvBapineuzumab (Elan/Wyeth) ：Phase III，monoclonal antibodiesvImmunoglobulin IgIV：Phase III，polyclonal antibodies2022-5-892022-5-810RAGE InhibitorvAmyloid is known to b

5、ind to receptors for advanced glycated endproducts (RAGE) on the surface of cells and at the blood-brain barrier； this binding may contribute to inflammation and neuronal death.vPF-04494700 ：an orally bioavailable antagonist of RAGE，Phase II 2022-5-811-secretase inhibitorsvTarenflurbil：the enantiome

6、r of the non-steroidal anti-inflammatory drug flurbiprofen，modulates the activity of -secretase，failed in Phase III vSemagacestat：reduction of amyloid peptide generation in blood and cerebrospinal fluid of patients with AD treated with tolerable doses， in Phase III2022-5-812Tau aggregation inhibitor

7、vRember（Methylene blue）：a widely used histology dye, has been shown to interfere with tau aggregation.v Entering Phase III2022-5-8132022-5-814Microtubule stabilizervNAP (AL-108)：derived from a natural neurotrophic protein, can be delivered to the central nervous system via intranasal administration.

8、vmarkedly reduces tau phosphorylation, and preliminary human studies have been encouraging.Now it is in Phase II trial.2022-5-815Dimebon-Pfizerv Phase III trial(Dimebon and Donepezil): failed，but Pfizer now is launching another Phase III trial about dimebon with other AD drugs.NNN2022-5-816vPhase II

9、I trials of Ginkgo biloba, NSAIDs, phenserine, statins, tarenflurbil, tramiprosate, and xaliproden have been completed, none of them demonstrating adequate efficacy.vPhase II trials of dimebon, huperzine A, intravenous immunoglobulin, and methylthioninium chloride were reported at 2008. vNineteen co

10、mpounds are currently in Phase II trials, and 3 compounds (AN1792, lecozotan SR, and SGS742) failed at this stage of development.2022-5-8173 TrendsvMultitarget Anti-Alzheimer AgentsvAD modelvfurther explore the causesvcoalition and cooperation2022-5-818Multitarget Anti-Alzheimer AgentsNovel Tacrine-

11、8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimers Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties2022-5-8192022-5-820Bivalent -Carbolines as Potential Multitarget Anti-Alzheimer Agents2022-5-821AD modelvA platform to perfor

12、m pharmacological evaluation of animal models of Alzheimers diseasevIn the future drug candidates may be directly used to animal models of Alzheimers disease2022-5-822Further explore the causesThe brain of AD patient likes a labyrinth 2022-5-823CooperationvWhile each of us is running into a stone wa

13、ll with Alzheimers ，what will we do next？vAllow researchers to study a larger pool of patients will help us see how the disease progresses, identify subgroups, and hopefully develop more sophisticated computer models that could save time and money developing drugs.2022-5-8244 PerspectivevWhile it is

14、 not possible to predict the success of any individual program, one or more are likely to prove effective.vDespite disappointing results from recently completed Phase III trials of several novel compounds, the extent and breadth of activity at all phases of clinical development suggest that new phar

15、macotherapeutic options for the treatment of AD will become available within the next decade. vIt seems reasonable to predict that in the not-too-distant future, a synergistic combination of agents will have the capacity to alter the neurodegenerative cascade and reduce the global impact of this dev

16、astating disease.2022-5-826Reference1 Michael S Rafii and Paul S Aisen.Recent developments in Alzheimers disease therapeutics.BMC Medicine 2009, 7:7 ,1741-7-15.2 Yvonne Rook.Bivalent -Carbolines as Potential Multitarget Anti-Alzheimer Agents.J.Med.C.XXXX,Vol.XXX,NO.XX3 Mara Isabel Fern andez-Bachill

17、er.Novel Tacrine-8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimers Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties.J.Med.C.XXXX,XXX,000-000.4 Raymond T. Bartus & Reginald L. Dean III.Pharmaceutical treatment for cognitive deficits in Alzheimers disease and other neurodegenerative conditions:exploring new territory using traditional tools and established maps.Psychopharmacology (2009) 202: